Immunohistochemical quantitation of thymidylate synthase expression in colorectal cancer metastases predicts for clinical outcome to fluorouracil- based chemotherapy

Journal of Clinical Oncology

Volumn 17, Issue 6, 1999, Pages 1760-1770

  Aschele, Carlo ^a   Debernardis, Domizia ^a   Casazza, Stefania ^a   Antonelli, Giovanna ^a   Tunesi, Gianni ^a   Baldo, Chiara ^a   Lionetto, Rita ^a   Maley, Frank ^a   Sobrero, Alberto ^a  

^a WADSWORTH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; FOLINIC ACID; METHOTREXATE; THYMIDYLATE SYNTHASE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; METASTASIS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; REGRESSION ANALYSIS; TUMOR GROWTH;

EID: 0032997572     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.1999.17.6.1760     Document Type: Article

References (53)

1. Bleiberg H: Colorectal cancer: Is there an alternative to 5-FU? Eur J Cancer 33:536-541, 1997
2. Advanced Colorectal Cancer Meta-Analysis Project: Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: Evidence in terms of response rate. J Clin Oncol 10:896-903, 1992
3. Lokich JJ, Ahlgren JD, Gullo JJ, et al: A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: A Mid-Atlantic Oncology Program study. J Clin Oncol 7:425-432, 1989
4. Rustum YM, Harstrick A, Cao S, et al: Thymidylate synthase inhibitors in cancer therapy: Direct and indirect inhibitors. J Clin Oncol 15:389-400, 1997
5. Zalcberg JR, Cunningham D, Van Cutsem E, et al: ZD1694: A novel thymidylate synthase inhibitor with substantial activity in the treatment of patients with advanced colorectal cancer - Tomudex Colorectal Study Group. J Clin Oncol 14:716-721, 1996
6. Pazdur R, Lasseve Y, Rhodes V, et al: Phase II trial of uracil and tegafur plus oral leucovorin: An effective oral regimen of metastatic colorectal carcinoma. J Clin Oncol 12:2288-2295, 1994
7. Taguchi T, Shirasaka T: New oral anticancer agent: S1. Ann Oncol 7:66, 1996 (abstr) (suppl 7)
8. Findlay M, Van Cutsem E, Kocha W, et al: A randomised phase II study of Xeloda™ (capecitabine) in patients with advanced colorectal cancer. Proc Am Soc Clin Oncol 16:227a, 1997 (abstr 798)
9. Pazdur R, Patt Y, Ajani J, et al: Phase II/pharmacology study of UFT (BMS-200604) and leucovorin in refractory colorectal cancer patients. Proc Am Soc Clin 16:270a, 1997 (abstr 959)
10. Leichman CG, Leichman L, Spears CP, et al: Prolonged continuous infusion of fluorouracil with weekly bolus leucovorin: A phase II study in patients with disseminated colorectal cancer. J Natl Cancer Inst 85:41-44, 1993
11. de Gramont A, Bosset JF, Milan C, et al: Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: A French Intergroup study. J Clin Oncol 15:808-815, 1997
12. Blijham G, Wagener T, Wils J, et al: Modulation of high dose infusional fluorouracil by low dose methotrexate in patients with advanced or metastatic colorectal cancer: Final results of a randomized European Organization for Research and Treatment of Cancer Study. J Clin Oncol 14:2266-2273, 1996
13. Wils JA: High-dose infusional 5-FU in the treatment of advanced colorectal cancer: A summary of the European experience. J Infus Chemother 6:145-148, 1996
14. Pazdur R, Vincent M, for the Tomudex Colorectal Cancer Study Group: Raltitrexed (Tomudex) versus 5-fluorouracil and leucovorin (5-FU + LV) in patients with advanced colorectal cancer (ACC): Results of a randomized, multicenter, North American trial. Proc Am Soc Clin Oncol 16:228a, 1997 (abstr 801)
15. Seitz JF, Cunningham D, Rath U, et al from the 'Tomudex' Study Group and Zeneca Pharmaceuticals: Final results and final data of a large randomised trial of 'Tomudex' in advanced colorectal cancer (ACC) confirm comparable efficacy to fluorouracil plus leucovorin (5FU + LV). Proc Am Soc Clin Oncol 15:201a, 1996 (abstr 446)
16. Conti JA, Kemeny NE, Saltz LB, et al: Irinotecan is an active agent in untreated patients with metastatic colorectal cancer. J Clin Oncol 14:709-715, 1996
17. Rothemberg ML, Eckardt JR, Kuhn JG, et al: Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer. J Clin Oncol 14:1128-1135, 1996
18. Rougier P, Bugat R, Douillard JY. et al: Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy. J Clin Oncol 15:251-260, 1997
19. Machover D, Diaz-Rubio E, de Gramont A, et al: Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines. Ann Oncol 7:95-98, 1996
20. de Gramont A, Vignoud J, Tournigand C, et al: Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer. Eur J Cancer 33:214-219, 1997
21. Washtein WL: Increased levels of thymidylate synthase in cells exposed to 5-fluorouracil. Mol Pharmacol 28:461-467, 1987
22. Berger SH, Jenh CH, Johnson LF, et al: Thymidylate synthase overproduction and gene amplification in fluorodeoxyuridine-resistant human cells. Mol Pharmacol 28:461-467, 1985
23. Chu E, Drake JC, Koeller DM, et al: Induction of thymidylate synthase associated with multidrug resistance in human breast and colon cancer cell lines. Mol Pharmacol 39:136-143, 1991
24. Clark JL, Berger SH, Mittelman A, et al: Thymidylate synthase gene amplification in a colon tumor resistant to fluoropyrimidine chemotherapy. Cancer Treat Rep 71:261-265, 1987
25. Peters GJ, Van Der Wilt CL, Van Groeningen CJ, et al: Thymidylate synthase inhibition after administration of fluorouracil with and without leucovorin in colon cancer patients: Implication for treatment with fluorouracil. J Clin Oncol 12:2035-2042, 1994
26. Mulder NH, Timmer-Bosscha H, Meersma GJ, et al: Thymidylate synthase levels in tumor biopsies from patients with colorectal cancer. Anticancer Res 146:2677-2680, 1994
27. Leichman CG, Lenz HJ, Leichman L, et al: Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin. J Clin Oncol 15:3223-3229, 1997
28. Johnston PG, Liang CM, Henry S, et al: Production and characterization of monoclonal antibodies that localize human thymidylate synthase in the cytoplasm of human cells and tissue. Cancer Res 51:6668-6676, 1991
29. Horikoshi T, Danenberg KD, Stadlbauer TH, et al: Quantitation of thymidylate synthase, dihydrofolate reductase, and DT-diaphorase gene expression in human tumors using the polymerase chain reaction. Cancer Res 52:108-116, 1992
30. Johnston PG, Fisher ER, Rockette HE, et al: The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer. J Clin Oncol 12:2640-2647, 1994
31. Johnston PG, Lenz HG, Leichman CG, et al: Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res 55:1407-1412, 1995
32. Pedersen-Lane J, Maley GF, Chu E, et al: High-level expression of human thymidylate synthase. Protein Expr Purif 10:256-262, 1997
33. Gorlick R, Metzger R, Danenberg D, et al: Higher levels of thymidylate synthase gene expression are observed in pulmonary as compared with hepatic metastases of colorectal adenocarcinoma. J Clin Oncol 16:1465-1469, 1998
34. Sobrero A, Aschele C, Bertino J: Fluorouracil in colorectal cancer: A tale of two drugs - Implication for biochemical modulation. J Clin Oncol 15:368-381, 1997
35. Sobrero AF, Aschele C, Guglielmi AP, et al: Schedule-selective biochemical modulation of 5-fluorouracil: A phase II study in advanced colorectal cancer. Clin Cancer Res 1:955-960, 1995
36. Aschele C, Guglielmi A, Frassineti GL, et al: Schedule-selective biochemical modulation of 5-fluorouracil in advanced colorectal cancer: A multicentric phase n study. Br J Cancer 77:341-346, 1998
37. Caroti C. Gallo L, Aschele C, et al: Sequential MTX → 5FU vs schedule specific biochemical modulation in advanced colorectal cancer. Proc Eighth Int Congress Anti-Cancer Treat 1998, p 96 (abstr O98)
38. Miller AB, Hoogstraten B, Staquet M, et al: Reporting results of cancer treatment. Cancer 47:207-214, 1981
39. Hsu SM, Raine L, Fanger H: A comparative study of the peroxidase-antiperoxidase method and an avidin biotin complex method for studying polypeptide hormones with radioimmunoassay antibodies. Am J Clin Pathol 5:734-738, 1981
40. Tong Y, Liu-Chen X, Ercikan-Abali EA, et al: Isolation and characterization of Thymitaq (AG337) and 5-fluoro-2-deoxyuridylate-resistant mutants of human thymidylate synthase from ethyl methanesulfonate-exposed human sarcoma HT1080 cells. J Biol Chem 273:11611-11618, 1998
41. Grem JL, Steinberg SM, Chen AP, et al: The utility of monitoring carcinoembryonic antigen (CEA) during systemic therapy for advanced colorectal cancer. Proc Am Soc Clin Oncol 16:269a, 1997 (abstr 954)
42. Kemeny N, Niedzwiecki D, Shurgot B, et al: Prognostic variables in patients with hepatic metastases from colorectal cancer. Cancer 63:742-747, 1989
43. Kemeny N, Braun DW: Prognostic factors in advanced colorectal carcinoma: Importance of lactic dehydrogenase level, performance status, and white blood cell count. Am J Med 74:786-794, 1983
44. Ardalan B, Cooney DA, Jayaram HN, et al: Mechanisms of sensitivity and resistance of murine tumors to 5-fluorouracil. Cancer Res 40:1431-1437, 1980
45. Myers CE, Young RC, Chabner BA: Biochemical determinants of 5-fluorouracil response in vivo: The role of deoxyuridylate pool expansion. J Clin Invest 56:1231-1238, 1975
46. Aschele C, Sobrero A, Faderan MA, et al: Novel mechanism(s) of resistance to 5-fluorouracil in human colon cancer (HCT-8) sublines following exposure to different clinically relevant dose schedules. Cancer Res 52:1855-1864, 1992
47. Wang FS, Aschele C, Sobrero A, et al: Decreased folylpolyglutamate synthetase expression: A novel mechanism of fluorouracil resistance. Cancer Res 53:3677-3680, 1993
48. Peters GJ, Van Der Wilt CL, Van Groeningen CJ: Predictive value of thymidylate synthase and dihydropyrimidine dehydrogenase. Eur J Cancer 10B:1408-1411, 1994
49. Belluco C, Guillem JG, Kemeny N, et al: p53 nuclear protein overexpression in colorectal cancer: A dominant predictor of survival in patients with advanced hepatic metastases. J Clin Oncol 14:2696-2701, 1996
50. Benhattar J, Cerottini JP, Saraga E, et al: p53 mutations as a possible predictor of response to chemotherapy in metastatic colorectal carcinomas. Int J Cancer 69:190-192, 1996
51. Schneider HJ, Sampson SA, Cunningham D, et al: Bcl-2 expression and response to chemotherapy in colorectal adenocarcinomas. Br J Cancer 75:427-431, 1997
52. Chu E, Koeller DM, Casey JL, et al: Autoregulation of human thymidylate synthase messenger RNA translation by thymidylate synthase. Proc Natl Acad Sci U S A 88:8977-8981, 1991
53. Findlay MPN, Cunningham D, Morgan G, et al: Lack of correlation between thymidylate synthase levels in primary colorectal tumours and subsequent response to chemotherapy. Br J Cancer 75:903-909, 1997